Drug intelligence / Profile preview

RS-009

Development stage: Preclinical
Lead developer: Related Sciences

Overview

RS-009 is a preclinical-stage drug candidate developed by Related Sciences. It is currently undergoing IND-enabling studies for the treatment of autoimmune and inflammatory diseases. Developed using Related Sciences' proprietary data science and machine learning platform, the specific molecular target and therapeutic modality of RS-009 have not yet been publicly disclosed.

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on RS-009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS-009.

Explore the full profile